CA2816911C - Novel treatment of multiple sclerosis (ms) - Google Patents

Novel treatment of multiple sclerosis (ms) Download PDF

Info

Publication number
CA2816911C
CA2816911C CA2816911A CA2816911A CA2816911C CA 2816911 C CA2816911 C CA 2816911C CA 2816911 A CA2816911 A CA 2816911A CA 2816911 A CA2816911 A CA 2816911A CA 2816911 C CA2816911 C CA 2816911C
Authority
CA
Canada
Prior art keywords
flurbiprofen
compound
compound according
coo
group selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2816911A
Other languages
English (en)
French (fr)
Other versions
CA2816911A1 (en
Inventor
Irmgard Tegeder
Gerd Geisslinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Publication of CA2816911A1 publication Critical patent/CA2816911A1/en
Application granted granted Critical
Publication of CA2816911C publication Critical patent/CA2816911C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2816911A 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms) Expired - Fee Related CA2816911C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis
GB1018519.7 2010-11-03
PCT/EP2011/069319 WO2012059541A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)

Publications (2)

Publication Number Publication Date
CA2816911A1 CA2816911A1 (en) 2012-05-10
CA2816911C true CA2816911C (en) 2018-09-25

Family

ID=43401688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816911A Expired - Fee Related CA2816911C (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)

Country Status (10)

Country Link
US (1) US20130309199A1 (enExample)
EP (1) EP2635271A1 (enExample)
JP (1) JP5903438B2 (enExample)
KR (1) KR101877587B1 (enExample)
CN (1) CN103209692A (enExample)
BR (1) BR112013010883A2 (enExample)
CA (1) CA2816911C (enExample)
GB (1) GB2485169A (enExample)
RU (1) RU2595861C2 (enExample)
WO (1) WO2012059541A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080989A1 (en) 2015-11-09 2017-05-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (r)-fluriprofen for the prevention and/or treatment of diabetes
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
BR112019017724A2 (pt) 2017-03-26 2020-03-31 Mapi Pharma Ltd. Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
BR112020008258B8 (pt) 2017-11-14 2023-01-31 Merck Sharp & Dohme Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)
CN113880899B (zh) * 2020-10-30 2023-06-23 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
CA2710318A1 (en) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellscaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
KR20130079353A (ko) * 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체

Also Published As

Publication number Publication date
RU2595861C2 (ru) 2016-08-27
KR101877587B1 (ko) 2018-07-11
KR20140017494A (ko) 2014-02-11
US20130309199A1 (en) 2013-11-21
JP2014505015A (ja) 2014-02-27
GB201018519D0 (en) 2010-12-15
GB2485169A (en) 2012-05-09
BR112013010883A2 (pt) 2016-09-13
RU2013125470A (ru) 2014-12-10
CA2816911A1 (en) 2012-05-10
CN103209692A (zh) 2013-07-17
JP5903438B2 (ja) 2016-04-13
WO2012059541A1 (en) 2012-05-10
EP2635271A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
CA2816911A1 (en) Novel treatment of multiple sclerosis (ms)
US11690831B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US6214874B1 (en) Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
Bai et al. TNFα in the trigeminal nociceptive system is critical for temporomandibular joint pain
AU2014204737A1 (en) Solid solution compositions and use in severe pain
JP2016538277A5 (enExample)
JP2011506505A (ja) 痛みを伴う神経障害の治療の際の、医薬並びにその製造方法及び使用
JP2021165304A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
AU2005200244A1 (en) Use of Riluzole for the Treatment of Multiple Sclerosis
AU2014403312A1 (en) Use in single pill/tablet/capsule of minocycline, fluconazole and atorvastatin in the treatment of multiple sclerosis
Jeong et al. The effect of mirogabalin on the treatment of intractable postherpetic neuralgia not responding appropriately to pregabalin: a case report
JP2018513862A (ja) シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体
WO2023109859A1 (zh) 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
Utheim Why Test BCG in Sjögren’s Syndrome?
Nugraha et al. Generalized pustular psoriasis in a 36-year-old female: clinical presentation and management
CA2918325C (en) Benzopyran derivatives useful as inhibitors of macrophage migrration inhibitory factor
Freo et al. Postoperative Bilateral Brachial Plexopathy in a Diabetic Patient
Aalbers ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients: drug trends in cardiology
Miyamoto Novel Treatment
EP1627663A2 (en) Use of a pharmaceutical composition for the treatment of pathologies derived from infection by herpes virus, papillomavirus, hepatitis virus, viral neuralgia, viral dsyplasia, immune-deficiency-induced viral infections and viral neuritis.
Hardy Injectable levetiracetam use in the dog.
Walling Combination Therapy for Rheumatoid Arthritis
Singh et al. M1743 Amelioration of Citrobacter rodentium Colitis by Apoe-Mimetic Peptide COG112 by Inhibition of NF-κB
Brown et al. M1744 An Inhibitor of Light but not Lymphotoxin β Ameliorates Colonic GVHD Induced by Transfer of Dba/2j Bone Marrow and T Cells Into B6d2f1 Mice
Funakoshi et al. A Novel NF-κB Inhibitor, DHMEQ, Ameliorates Inflammatory Colonic Injuries in Mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160428

MKLA Lapsed

Effective date: 20211103